Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol

Pain Clinical Trial

— PREDICT  

Official title:

Impact of CYP2D6 Genetic Polymorphism on the Vulnerability to Drug-drug Interactions With Tramadol: a Gene-environment Interaction and Phenoconversion Study on Patients Undergoing a Steady Treatment With a Potent CYP2D6 Inhibitor.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04249674
• Other study ID #: 2019-01418
• Status: Recruiting
• Start date: November 4, 2019
• Est. completion date: December 2022

Study information

• Verified date: January 2022
• Source: University Hospital, Geneva
• Contact: Caroline Samer, Doctor
• Phone: 022 372 99 47
• Email: caroline.samer[@]hcuge.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite its poor abundance in the liver, CYP2D6 is the second most important CYP in drug metabolism, metabolizing 20% of drugs. The high inter-individual variability in CYP2D6 expression is explained by genetic variations, but also by drug-drug interactions (DDIs). Recent studies have pointed out the poor therapeutic predictable value of DDI. Indeed, the clinical outcomes of a DDI may involve several intrinsic factors affecting the vulnerability to and extent of DDI, such as genetic polymorphisms, comorbidities, age and sex.

In this regard, the present research project aims to investigate the effect of genetic polymorphism on DDIs involving CYP2D6 (gene-environment interaction) and its implications for tramadol efficacy and safety in a clinical setting. In a previous study, we demonstrated differences in both the rate of phenoconversion and the magnitude of DDI in healthy volunteers, that were either heterozygote normal metabolizers (NMs) carrying a non-functional CYP2D6 allele (activity score (AS) 1) and homozygous NM carrying two fully-functional CYP2D6 alleles (AS 2).

This prospective study will include patients scheduled for a general surgery of less than 3 hours and planned to be treated with oral tramadol as a routine post-operative pain management.

Patients taking part in the study may receive diagnosis, therapeutic or other interventions but the groups of individuals (controls vs inhibited) are predefined based on the routine treatment of the patients.

There will be no assigned specific interventions to the study participants and CYP2D6 phenotypes will be classified in five activity score groups (0.5, 1, 1.5, 2, >2) in the absence or presence of a potent CYP2D6 inhibitor received as part of routine medical care.

PK of tramadol and its active metabolite (M1), as well as its analgesic and PD effects and safety, will be compared between groups. Finally, the data generated will be used to build a physiologically-based PK (PBPK) model for tramadol in different sub-groups. The model will aim to predict the effect of CYP2D6 inhibition in virtual populations with different genetically-related CYP2D6 activities. This should allow prospective dose adjustment of tramadol (or appropriate drug selection) based on patients' genotype in the presence of a CYP2D6 inhibitor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 172
• Est. completion date: December 2022
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any male and female patients > 18 years scheduled for a surgery of less than 3 hours duration and planned to be treated with oral tramadol as a routine management of post-operative pain;

• Patients with physical conditions classified as ASA I to III, based on American Society of Anesthesiology classification;

• Patients treated chronically with a potent CYP2D6 inhibitor (for CYP2D6-inhibited arms only);

• Understanding of French language and able to give a written inform consent

Exclusion Criteria:

• Pregnant or breastfeeding woman

• Any pathologies, use of drugs or food that may affect CYP activity (for control arms only and based on the 'drug interactions and cytochromes P450' table published by The Service of clinical Pharmacology and Toxicology [3], HUG and on the investigator's knowledge)

• Liver transplantation history

• Sensitivity to dextromethorphan (CYP2D6 probe drug) or any contra-indication to dextrometorphan

• Medical history of cirrhosis (Child Pugh B and C) or/and hepatosteatosis.

• Glomerular filtration rate (GFR) < 30 ml/min/1.73m2

Related Conditions & MeSH terms

• Interaction
• Pain

Intervention

Diagnostic Test:
• Dextrometorphan
Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Genetic:
• Genotyping by single nulcetoide polymorphism.
Single nucleotide polymorphism determination

Locations

Country	Name	City	State
Switzerland	Geneva University Hospitals, HUG	Genève

Sponsors (6)

Lead Sponsor	Collaborator
University Hospital, Geneva	Bernard Walder, Eduardo Schiffer, Jules Desmeules, Kenza Abouir, Youssef Daali

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Urinary metabolic ratio (UMR) tramadol/M1 in urine collection		8 hours
Other	Saliva metabolic ratio tramadol/M1		2 hours
Primary	Assess the proportion of patients in each group who acquires a phenotype switch (phenoconversion) with or without CYP2D6 inhibitor.		10 hours
Secondary	Comparison of Tramadol , Dexrometorphan and their metabolites maximum plasma concentration (Cmax) according to patient belonging to the control or inhibited group.		24 hours
Secondary	Comparison of Tramadol, Dextrometorphan and their metabolites Area Under the curve (AUC) according to patient belonging to the control or to the inhibited group and to his CYP2D6 phenotype		24 hours
Secondary	Comparison of Tramadol, Dextrometorphan and their metabolites Clearance (CL) according to patient belonging to the control or to the inhibited group.		24 hours